# A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

> **NCT04007367** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 53 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** SAGE-217
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04007367
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-06
- **Primary completion:** 2020-01-06
- **Final completion:** 2020-01-06
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Internal company decision
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04007367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04007367, "A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04007367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*